Sequelae of doping with anabolic steroids

Testosterone: Action, Deficiency, Substitution, Fourth Edition

Volumn , Issue , 2012, Pages 535-546

  Vorona, Elena ^a   Nieschlag, Eberhard ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84896766780     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9781139003353.026     Document Type: Chapter

References (90)

1. Achar S, Rostamian A, Narayan SM (2010) Cardiac and metabolic effects of anabolic-androgenic steroid abuse on lipids, blood pressure, left ventricular dimensions, and rhythm. Am J Cardiol 106:893-901
2. Anderson GL, Limacher M, Assaf AR, Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, nJackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291:1701-1712
3. Alén M (1985) Androgenic steroid effects on liver and red cells. Br J Sports Med 19:15-20
4. Andò S, De Amicis F, Rago V, Carpino A, Maggiolini M, Panno ML, Lanzino M (2002) Breast cancer: from estrogen to androgen receptor. Mol Cell Endocrinol 193:121-128
5. Babigian A, Silverman RT (2001) Management of gynecomastia due to use of anabolic steroids in bodybuilders. Plast Reconstr Chir 1:240-242
6. Baker J (1999) A report on alterations to the speaking and singing voices of four women following hormonal therapy with virilizing agents. J Voice 13:496-507
7. Bauer G (1973) Klinik der Stimmstörungen. In: Biesalski P (ed) Phoniatrie. Thieme-Verlag, Stuttgart, pp 165-172
8. Basaria S (2010) Androgen abuse in athletes: detection and consequences. J Clin Endocrinol Metab 95:1533-1543
9. Berendonk M (1991) Doping- Dokumente. Von der Forschung zum Betrug. Springer-Verlag, Berlin
10. Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, Bunnell TJ, Tricker R, Shirazi A, Casaburi R (1996) The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 335:1-7
11. Bonetti A, Tirelli F, Catapano A, Dazzi D, Dei Cas A, Solito F, Ceda G, Reverberi C, Monica C, Pipitone S, Elia G, Spattini M, Magnati G (2008) Side effects of anabolic androgenic steroids abuse. Int J Sports Med 29:679-687
12. Braunstein GD (2007) Safety of testosterone treatment in postmenopausal women. Fertil Steril 88:1-16
13. Burcombe RJ, Makris A, Pittam M, Finer N (2003) Breast cancer after bilateral subcutaneous mastectomy in a female-to-male transsexual. Breast 12:290-293
14. Caso P, D’Andrea A, Caso I, Severino S, Calabrò P, Allocca F, Mininni N, Calabrò R (2006) The athlete's heart and hypertrophic cardiomyopathy: two conditions which may be misdiagnosed and coexistent. Which parameters should be analysed to distinguish one disease from the other? J Cardiovasc Med (Hagerstown) 7:257-266
15. Clark BM, Schofield RS (2005) Dilated cardiomyopathy and acute liver injury associated with combined use of ephedra, gammahydroxybutyrate and anabolic steroids. Pharmacotherapy 25:756-761
16. Clasing D, Müller RK (2008) Dopingkontrolle, 5th edn. Sportverlag Strauß, Cologne
17. de Gooyer ME, Oppers-Tiemissen HM, Leysen D, Verheul HA, Kloosterboer HJ (2008) Tibolone is not converted by human aromatase to 7alpha-ethynylestradiol (7alpha-MEE): analyses with sensitive bioassays for estrogens and androgens and with LC-MSMS. Steroids 68:235-243
18. De Piccoli B, Giada F, Benettin A, Sartori F, Piccolo E (1991) Anabolic steroid use in body builders: an echocardiographic study of the left ventricle morphology and function. Int J Sports Med 12:408-412
19. Deshmukh N, Petroczi A, Barker J, Szekely AD, Hussain I, Naughton DP (2010) Potentially harmful advantage to athletes: a putative connection between UGT2B17 gene deletion polymorphism and renal disorders with prolonged use of anabolic androgenic steroids. Subst Abuse Treat Prev Pol 5:1-7
20. Di Bello V, Giorgi D, Bianchi M, Bertini A, Caputo MT, Valenti G, Furioso O, Alessandri L, Paterni M, Giusti C (1999) Effects of anabolicandrogenic steroids on weightlifters’ myocardium: an ultrasonic videodensitometric study. Med Sci Sports Exerc 31:514-521
21. Dickerman RD, Schaller F, Prather I, McConathy WJ (1995) Sudden cardiac death in a 20-year-old bodybuilder using anabolic steroids. Cardiology 86:172-173
22. Dickerman RD, Schaller F, McConathy WJ (1998) Left ventricular wall thickening does occur in elite power athletes with or without anabolic steroid use. Cardiology 90:145-148
23. Dimitrakakis C, Jones RA, Liu A, Bondy CA (2004) Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy. Menopause 11:531-535
24. Evans NA (1997) Gym and tonic: a profile of 100 male steroid users. Br J Sports Med 31:54-58
25. Ferenchick GS, Hirokawa S, Mammen EF, Schwartz KA (1995) Anabolicandrogenic steroid abuse in weight lifters: evidence for activation of the hemostatic system. Am J Hematol 49:282-288
26. Ferriman DM, Gallwey JD (1961) Clinical assessment of body hair growth in women. J Clin Endocrinol 21:1440-1447
27. Fineschi V, Baroldi G, Monciotti F, Paglicci Reattelli L, Turillazi E (2001) Anabolic steroid abuse and cardiac sudden death: a pathologic study. Arch Pathol Lab Med 125:253-255
28. Fischer-Solms H (2009) Spitzensport: Doping in Ost und West. In: Stiftung Haus der Geschichte der Bundesrepublik Deutschland, Wir gegen uns: Sport im geteilten Deutschland. Primus-Verlag, Darmstadt, pp 111-121
29. Franke WW, Berendonk B (1997) Hormonal doping and androgenization of athletes: a secret program of the German Democratic Republic government. Clin Chem 43:1262-1279
30. Froehner M, Fischer R, Leike S, Hakenberg OW, Noack B, Wirth MP (1999) Intratesticular leiomyosarcoma in a young man after high dose doping with Oral- Turinabol. Cancer 86:1571-1575
31. Fronczak CM, Kim ED, Barqawi AB (2011) The insults of illicit drug use on male fertility. J Androl Jul 28 [Epub ahead of print]
32. Gerber PA, Kukova G, Meller S, Neumann NJ, Homey B (2008) The dire consequences of doping. Lancet 372:656
33. Giannitrapani L, Soresi M, La Spada E, Cervello M, D’Alessandro N, Montalto G (2006) Sex hormones and risk of liver tumor. Ann N Y Acad Sci 1089:228-236
34. Gooren LJ, Giltay EJ, Bunk MC (2008) Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience. J Clin Endocrinol Metab 93:19-25
35. Gruber A, Pope HG Jr (2000) Psychiatric and medical effects of anabolic-androgenic steroid use in women. Psychother Psychosom 69:19-26
36. Hartgens F, Kuipers H (2004) Effects of androgenic-anabolic steroids in athletes. Sport Med 34:513-554
37. Hartgens F, Rietjens G, Keizer HA, Kuipers H, Wolffenbuttel BH (2004) Effects of androgenicanabolic steroids on apolipoproteins and lipoprotein (a). Br J Sports Med 38:253-259
38. Hendriks AE, Boellaard WP, van Casteren NJ, Romijn JC, de Jong FH, Boot AM, Drop SL (2010) Fatherhood in tall men treated with high-dose sex steroids during adolescence. J Clin Endocrinol Metab 95:5233-5240
39. Hofling M, Hirschberg AL, Skoog L, Tani E, Hägerström T, von Schoultz B (2007) Testosterone inhibits etrogen/progestogen-induced breast cell proliferation in postmenopausal women. Menopause 14:183-190
40. Johnson CA (2000) Use of androgens in patients with renal failure. Semin Dial 13:36-39
41. Kahn NN, Sinha AK, Spungen AM, Bauman WA (2006) Effects of oxandrolone, an anabolic steroid, on hemostasis. Am J Hematol 81:95-100
42. Kanayama G, Brower KJ, Wood RI, Hudson JI, Pope HG Jr (2010) Treatment of anabolic-androgenic steroid dependence: emerging evidence and its implications. Drug Alcohol Depend 109:6-13
43. Karila TA, Karjalainen JE, Mäntysaari MJ, Viitasalo MT, Seppälä TA (2003) Anabolic androgenic steroids produce dose-dependant increase in left ventricular mass in power athletes, and this effect is potentiated by concomitant use of growth hormone. Int J Sports Med 24:337-343
44. Kindermann W (2006) Kardiovaskuläre Nebenwirkungen von anabol-androgenen Steroiden. Herz 31:566-573
45. Kirkham H, Algard FT (1965) Characteristic of an androgen/estrogen dependent leiomyosarcoma of the ductus deferens of the Syrian hamster. I. In vivo. Cancer Res 25:141-146
46. Kistler L (2006) Todesfälle bei Anabolikamissbrauch. Todesursache, Befunde und rechtsmedizinische Aspekte. Dissertation for Doctor of medicine at the Medical Faculty of the Ludwig-Maximilian University in Munich
47. Kley HK (2004) Anabole Steroide - pharmakologische Wirkung der Dopingmittel. In: Clasing D (ed) Doping und seine Wirkstoffe. Verbotene Arzneimittel im Sport Spitta Verlag, Balingen, pp 64-84
48. Knuth UA, Maniera H, Nieschlag E (1989) Anabolic steroids and semen parameters in bodybuilders. Fertil Steril 52:1041-1047
49. Labhart A (1978) Klinik der inneren Sekretion, 3rd edn. Springer-Verlag, Heidelberg, pp 1039-1040
50. Lapointe J, Fournier A, Richard V, Labrie C (1999) Androgens downregulate bcl-2 prooncogene expression in ZR-75-1 human breast cancer cells. Endocrinology 140:416-421
51. Lemcke B, Zentgraf J, Behre HM, Kliesch S, Bramswig JH, Nieschlag E (1996) Long-term effects on testicular function of high-dose testosterone treatment for excessively tall stature. J Clin Endocrinol Metab 81: 296-301
52. Lindberg MK, Vandenput L, Movèrare Skrtic S, Vanderschueren D, Boonen S, Bouillon R, Ohlsson C (2005) Androgens and the skeleton Minerva Endocrinol 30:15-25
53. Magnusson C, Baron JA, Correia N, Bergström R, Adami H-O, Persson I (1999) Breast cancer risk following long-term oestrogen and oestsrogen-progestin-replacement therapy. Int J Cancer 81:339-344
54. Maisch B, Richter A, Sandmöller A, Porting I, Pankuweit S (2005) Inflammatory dilated cardiomyopathy (DCMI). Herz 30:535-544
55. Million Women Study Collaborators (2003) Breast cancer and hormonereplacement therapy in the Million Women Study. The Lancet 362:419-427
56. Mueller A, Gooren L (2008) Hormonerelated tumors in transsexuals receiving treatment with cross-sex hormones. Europ J Endocrinol 159:197-202
57. Nakao A, Sakagami K, Nakata Y, Komazawa K, Amimoto T, Nakashima K, Isozaki H, Takakura N, Tanaka N (2000) Multiple hepatic adenomas caused by longterm administration of androgenic steroids for aplastic anemia in association with familial adenomatous polyposis.J Gastoenterol 35:557-562
58. Nieschlag E (1981) Ist die Anwendung von Methyltestosteron obsolet? Dtsch Med Wochenschr 106:1123-1125
59. Nieschlag E, Behre HM, Nieschlag S (eds) (2010) Andrology. Male Reproductive Health and Dysfunction, 3rd edn. Springer- Verlag, Berlin, pp 437-455
60. Nygren U, Södersten M, Falhammar H, Thorén M, Hagenfeldt K, Nordenskjöld A (2009) Voice characteristics in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clin Endocrinol 70:18-25
61. Ortmann J, Prifti S, Bohlmann MK, Rehberger-Schneider S, Strowitzki T, Rabe T (2002) Testosterone and 5 alpha-dihydrotestosterone inhibit in vitro growth of human breast cancer cell lines. Gynecol Endocrinol 16:113-120
62. O'sullivan AJ, Kennedy MC, Casey JH, Day RO, Corrigan B, Wodak AD (2000) Anabolic-androgenic steroids: medical assessment of present, past and potential users. Med J Aust 173:323-327
63. Parkinson AB, Evans NA (2006) Anabolic androgenic steroids: a survey of 500 users. Med Sci Sports Exerc 38:644-651
64. Przkora R, Jeschke MG, Barrow RE, Suman OE, Meyer WJ, Finnerty CC, Sanford AP, Lee J, Chinkes DL, Mlcak RP, Herndon DN (2005) Metabolic and hormonal changes of severely burned children receiving long-term oxandrolone treatment. Ann Surg 242:384-389
65. Rolf C, Nieschlag E (1998) Potential adverse effects of long-term testosterone therapy. Baillieres Clin Endocrinol Metab 12:521-534
66. Schollert PV, Bendixen PM (1993) Dilated cardiomyopathy in a user of anabolic steroids. Ugeskr Laeger 155:1217-1218
67. Sculthorpe N, Grace F, Jones P, Davies B (2010) Evidence of altered cardiac electrophysiology following prolonged androgenic anabolic steroid use. Cardiovasc Toxicol 10:239-243
68. Shapiro J, Christiana J, Frishman W (1999) Testosterone and other anabolic steroids as cardiovascular drugs. Am J Ther 6:167-174
69. Sinner D, Bachmann M (2004) Anabole Steroide. Das schwarze Buch. BMS Verlag, Gronau, pp 47-49, 561-563
70. Sjöqvist F, Garle M, Rane A (2008) Use of doping agents, particularly anabolic steroids, in sports and society. Lancet 371:1872-1882
71. Somboonporn W, Davis SR (2004) Testosterone effects on the breast: implications for testosterone therapy for women. Endocr Rev25:374-388
72. Steinigen J (2003) Zivilrechtliche Aspekte des Dopings aus der Sicht des Spitzensportlers. Weißensee Verlag, Berlin
73. Strauss RH, Liggett MT, Lanese RR (1985) Anabolic steroid use and perceived effects in ten weighttrained women athletes. JAMA 253:2871-2873
74. Sullivan ML, Martinez CM, Gennis P, Gallagher EJ (1998) The cardiac toxicity of anabolic steroids. Prog Cardiovasc Dis 41:1-15
75. Toorians A, Thomassen M, Zweegman S, Magdeleyns E, Tans G, Gooren L, Rosing J (2003) Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people. J Clin Endocrinol Metab 88:5723-5729
76. Turillazzi E, Perilli G, Di Paolo M, Neri M, Riezzo I, Fineschi V (2011) Side effects of AAS abuse: an overview. Mini Rev Med Chem 11:374-389
77. Urman B, Pride SM, Yuen BH (1991) Elevated serum testosterone, hirsutism, and virilism associated with combined androgen-estrogen hormone replacement therapy. Obstet Gynecol 77:595-598
78. Vanderschueren D, Vandenput L, Boonen S, Lindenberg M, Bouillon R, Ohlsson C (2004) Androgens and bone. Endocr Rev 25:389-425
79. Van Staa TP, Sprafka JM (2009) Study of adverse outcomes in women using testosterone therapy. Maturitas 62:76-80
80. Van Winkle W Jr (1949) The action of steroid hormones in mammary cancer. Radiology 53:530-539
81. Vogt AM, Geyer H, Jahn L, Schänzer W, Kübler W (2002) Cardiomyopathy associated with uncontrolled self medication of anabolic steroids. Z Kardiol 91:357-362
82. Walker J, Adams B (2009) Cutaneous manifestations of anabolic- androgenic steroid use in athletes. Int J Dermatol 48:1044-1048
83. Wollina U, Pabst F, Schönlebe J, Abdel- Naser MB, Konrad H, Gruner M, Haroske G, Klemm E, Schreiber G (2007) Side-effects of topical androgenic and anabolic substances and steroids. A short review. Acta Dermatoven APA 16:117-122
84. Winkler U (1996) Effects of androgens on haemostasis. Maturitas 24:147-155
85. Wirth G (1979) Stimmstörungen. Dtsch Ärzteverlag, Cologne
86. Woodhouse LJ, Gupta N, Bhasin M, Singh AB, Ross R, Phillips J, Bhasin S (2004) Dose-dependent effects of testosterone on regional adipose tissue distribution in healthy young men. J Clin Endocrinol Metab 89:718-726
87. Zhou J, Ng S, Adesanya-Famuiya O, Anderson K, Bondy CA (2000) Testosterone inhibits estrogeninduced mammary epithelial proliferation and suppresses estrogen receptor expression. FASEB J 14:1725-1730
88. Zitzmann M, Nieschlag E (2007) Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. J Clin Endocrinol Metab 92:3844-3853
89. Zitzmann M, Junker R, Kamischke A, Nieschlag E (2002) Contraceptive steroids influence the hemostatic activation state in healthy men. J Androl 23:503-511
90. Zouboulis CC, Chen WC, Thornton MJ, Qin K, Rosenfield R (2007) Sexual hormones in human skin. Horm Metab Res 39:85-95